For decades, researchers have wondered why some people with risky gene variants go on to develop Parkinson’s disease, while ...

Roche and Prothena are advancing Prazinezumab to Phase 3 for Parkinson’s, despite mixed Phase 2 results, due to promising ...

A large longitudinal study found that pesticide exposure and caffeinated soda intake were linked to more severe motor ...

Jefferies analysts said on Tuesday that Ventyx could leverage its mid-stage data for VTX3232 to position the oral drug candidate as a treatment for other neurodegenerative diseases, including ...

Ventyx Biosciences has shared phase 2a data on a Parkinson’s disease prospect that has caught the eye of Sanofi. The readout shows the effect of VTX3232 on biomarkers, providing some of the data that ...

They were designed to treat diabetes, then prescribed for weight loss, and now—as researchers are finding—they might hold the ...

The University of California, San Francisco (UCSF) has received a $5 million donation from the Jean Pierre “JP” Conte Family ...

Known as much for their innovative videos and for their hits such as “Take on Me”, “Cry Wolf”, the band’s frontman shared ...

Basel: Roche has announced its decision to proceed with Phase III development of prasinezumab, an investigational ...

Cleveland Clinic Abu Dhabi, part of the M42 group, has successfully introduced continuous infusion therapy, a cutting-edge ...

Psilocybin therapy improved cognitive performance, reduced mood dysfunction, motor, and nonmotor symptoms in patients with Parkinson disease.

Roche to advance prasinezumab into phase III development for early-stage Parkinson's disease: Basel Tuesday, June 17, 2025, 09:00 Hrs [IST] Roche announced its decision to proceed ...